Thursday, October 14, 2021 4:00pm to 5:00pm
About this Event
Join us for a chat with Tyler Brown, PhD '19, and bioengineering professor Samir Mitragotri as they share the founding story of i2O.
i2O Therapeutics was launched to develop safe and effective oral formulations for a range of biologics, large molecules, and peptide-based pharmaceuticals, with an initial focus on developing formulations for GLP1 analogs, glucagon-like peptides that help balance glucose levels to treat diabetes. The foundational technology – based on ionic liquids – was developed in the Mitragotri Lab with support from Harvard's Blavatnik Biomedical Accelerator.
0 people are interested in this event